Nintedanib (BIBF 1120) in Mesothelioma
Launched by BOEHRINGER INGELHEIM · Jul 22, 2013
Trial Information
Current as of August 11, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • Histologically confirmed malignant pleural mesothelioma (MPM) (Epithelioid or biphasic subtype for Phase II patients; epithelioid subtype only for Phase III patients)
- • Life expectancy of at least 3 months in the opinion of the investigator
- • Eastern Cooperative Oncology Group (ECOG) score of 0 or 1
- • Measurable disease according to modified RECIST (Response Evaluation Criteria In Solid Tumours) criteria
- Exclusion criteria:
- • Previous systemic chemotherapy for MPM
- • Prior treatment with nintedanib or any other prior line of therapy
- • Phase II patients with sarcomatoid subtype MPM or Phase III patients with biphasic or sarcomatoid subtype MPM
- • Patients with symptomatic neuropathy
- • Radiotherapy (except extremities) within 3 months prior to baseline imaging
- • Active brain metastases (e.g. stable for \< 4 weeks)
- • Radiographic evidence of cavitary or necrotic tumours or local invasion of major blood vessels by MPM
- • Significant cardiovascular diseases
- • Inadequate hematologic, renal, or hepatic function
About Boehringer Ingelheim
Boehringer Ingelheim is a global, research-driven pharmaceutical company dedicated to improving health and quality of life through innovative therapies. Established in 1885 and headquartered in Ingelheim, Germany, the company focuses on the development of prescription medicines in key therapeutic areas, including respiratory diseases, cardiovascular health, oncology, and immunology. Boehringer Ingelheim is committed to advancing medical science through rigorous clinical trials and collaborative research, striving to bring novel treatments to patients while upholding the highest standards of safety and efficacy. With a strong emphasis on sustainability and corporate responsibility, the company aims to make a meaningful impact on global health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Birmingham, Alabama, United States
Sudbury, Ontario, Canada
Box Hill, Victoria, Australia
San Francisco, California, United States
London, , United Kingdom
Birmingham, Alabama, United States
Barcelona, , Spain
Nedlands, Western Australia, Australia
Haifa, , Israel
Henderson, Nevada, United States
Uppsala, , Sweden
Houston, Texas, United States
Pittsburgh, Pennsylvania, United States
Madrid, , Spain
Valencia, , Spain
Heidelberg, Victoria, Australia
Barcelona, , Spain
Malaga, , Spain
Tel Aviv, , Israel
Leicester, , United Kingdom
Edinburgh, , United Kingdom
Leoben, , Austria
Leuven, , Belgium
Glasgow, , United Kingdom
Sevilla, , Spain
Chermside, Queensland, Australia
Homburg/Saar, , Germany
Cairo, , Egypt
Brno, , Czechia
Greenville, South Carolina, United States
Toluca, , Mexico
Berlin, , Germany
Enschede, , Netherlands
Bruxelles, , Belgium
Toronto, Ontario, Canada
Großhansdorf, , Germany
Löwenstein, , Germany
Poznan, , Poland
Kazan, , Russian Federation
Moscow, , Russian Federation
Mcallen, Texas, United States
Rotterdam, , Netherlands
Waratah, New South Wales, Australia
Wels, , Austria
Gent, , Belgium
London, , United Kingdom
Sutton, , United Kingdom
Leuven, Vlaams Brabant, Belgium
Frankston, Victoria, Australia
Edegem, , Belgium
Heerlen, , Netherlands
Siena, , Italy
Genova, , Italy
Littleton, Colorado, United States
Chihuahua, , Mexico
Göteborg, , Sweden
Linköping, , Sweden
Lund, , Sweden
Stockholm, , Sweden
Caen, , France
Villejuif, , France
Mexico, , Mexico
Izmir, , Turkey
Marseille, , France
Toulouse, , France
Berlin, , Germany
Orbassano (To), , Italy
Olomouc, , Czechia
Aviano (Pn), , Italy
Gdansk, , Poland
Lisboa, , Portugal
Cairo, , Egypt
Poznan, , Poland
Porto, , Portugal
Saint Petersburg, , Russian Federation
Valencia, Comunidad Valenciana, Spain
San Antonio, Texas, United States
Spokane Valley, Washington, United States
Ciudad Autónoma De Bs As, , Argentina
Ciudad Autónoma De Bs As, , Argentina
Ciudad De Cordoba, , Argentina
St Leonards, New South Wales, Australia
South Brisbane, Queensland, Australia
Wodonga, Victoria, Australia
Perth, Western Australia, Australia
Vienna, , Austria
Mechelen, , Belgium
Halifax, Nova Scotia, Canada
Quebec, , Canada
Recoleta, , Chile
Vitacura, , Chile
Zagreb, , Croatia
Købenahvn ø, , Denmark
Alexandria, , Egypt
Alexandria, , Egypt
Bordeaux, , France
Brest, , France
Lille, , France
Pierre Bénite, , France
Toulon, , France
Gerlingen, , Germany
Heidelberg, , Germany
Petach Tikva, , Israel
Alessandria, , Italy
Bergamo, , Italy
Fukuoka, Kitakyushu, , Japan
Hyogo, Amagasaki, , Japan
Hyogo, Nishinomiya, , Japan
Kanagawa , Yokosuka, , Japan
Okayama, Okayama, , Japan
Osaka, Osakasayama, , Japan
Osaka, Osaka, , Japan
Tokyo, Bunkyo Ku, , Japan
Oslo, , Norway
Trondheim, , Norway
Warsaw, , Poland
Chelyabinsk, , Russian Federation
Saint Petersburg, , Russian Federation
Ufa, , Russian Federation
Pretoria, , South Africa
Barakaldo (Vizcaya), , Spain
Donostia (Gipuzkoa), , Spain
L'hospitalet De Llobregat, , Spain
Eskisehir, , Turkey
Istanbul, , Turkey
Wythenshawe, , United Kingdom
Patients applied
Trial Officials
Boehringer Ingelheim
Study Chair
Boehringer Ingelheim
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials